Combination Obeticholic Acid (OCA) and Statins for Monitoring of Lipids (CONTROL)
- Conditions
- Nonalcoholic Steatohepatitis
- Interventions
- Registration Number
- NCT02633956
- Lead Sponsor
- Intercept Pharmaceuticals
- Brief Summary
This Phase 2, double-blind, randomized, placebo-controlled, multicenter study, with an open-label long-term safety extension (LTSE), will evaluate the effect of Obeticholic Acid, and the subsequent addition of statin therapy, on lipoprotein metabolism in subjects with nonalcoholic steatohepatitis (NASH) with fibrosis stage 1 to 4, but no evidence of hepatic decompensation.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 84
- Age ≥18 years
- Histologic evidence of NASH, as assessed by central reading of a liver biopsy obtained no more than 1 year prior to randomization, defined by the presence of all 3 key histological features of NASH with a score of at least 1 for each and a combined score of 4 or greater out of a possible 8 points according to NASH Clinical Research Network (CRN) criteria.
- Histologic evidence of fibrosis stage 1 to stage 4 (as defined by NASH CRN scoring of fibrosis) without any evidence of hepatic decompensation.
- If subject has type 2 diabetes, is on stable dose of anti-diabetic medication (except thiazolidinediones [TZDs]) for ≥3 months prior to Day 1.
- Is either not taking or is on stable doses of TZDs and/or Vitamin E for ≥6 months prior to Day 1.
- Contraception: Female subjects of childbearing potential must use ≥1 effective method of contraception during the study and until 30 days following the last dose of investigational product. Effective methods of contraception are considered to be the following: barrier method, ie, condom (male or female) with spermicide or diaphragm with spermicide, intrauterine device, vasectomy (partner), hormonal (eg, contraceptive pill, patch, intramuscular implant or injection), abstinence (defined as refraining from heterosexual intercourse).
- Must provide written informed consent and agree to comply with the study protocol, including adherence to protocol-described statin withdrawal and statin therapy.
-
Current or history of significant alcohol consumption for a period of more than 3 consecutive months within 1 year prior to Screening Visit 1 (significant alcohol consumption is defined as more than 2 units/day in females and more than 4 units/day in males, on average)
-
Prior intolerance to treatment with atorvastatin or other 3-hydroxy-3-methyl-glutaryl (HMG) Coenzyme A reductase inhibitors (including but not limited to rhabdomyolysis).
-
LDL cholesterol ≥190 mg/dL and already on statin therapy at Screening Visit 1.
-
LDL cholesterol >200 mg/dL at any Screening Visit in subjects who are not on statin therapy, or at Screening Visit 2 in statin washout subjects.
-
Planned change in diet or exercise habits during participation in the double-blind period, or a significant weight change of >5% in the prior 6 months.
-
Subjects who have undergone gastric bypass procedures (gastric lap band is acceptable) or ileal resection or plan to undergo either of these procedures.
-
History of biliary diversion
-
Uncontrolled diabetes defined as HbA1c ≥9.5% within 60 days prior to randomization (Day 1).
-
Administration of any of the following medications as specified below:
-
Prohibited 30 days prior to Day 1:
- bile acid sequestrants (BAS) including cholestyramine and its derivatives, colesevelam, colestipol, or
- omega-3 fatty acid-containing dietary supplements
-
Prohibited 3 months prior to Day 1:
- nicotinic acid and derivatives, ezetimibe
- any prescription or over-the-counter (OTC) medication or herbal remedy with putative NASH efficacy (except Vitamin E or TZDs)
- ursodeoxycholic acid
- fenofibrate or other fibrates
- any OTC or health food used to treat lipids including plant sterols and berberine
-
Prohibited 6 months prior to Day 1:
- azathioprine, colchicine, cyclosporine, methotrexate, mycophenolate, mofetil, pentoxifylline; budesonide and other systemic corticosteroids, or
- potentially hepatotoxic drugs (including α-methyl-dopa, sodium valproic acid, isoniazide, or nitrofurantoin)
-
Prohibited 12 months prior to Day 1:
- antibodies or immunotherapy directed against interleukins, or
- other cytokines or chemokines
-
-
Evidence of other forms of chronic liver disease including but not limited to:
- Positive test result at Screening for hepatitis B surface antigen
- Active hepatitis C virus (HCV) infection (positive for HCV ribonucleic acid [RNA] at Screening) or history of positive HCV RNA test result
- Primary biliary cirrhosis, primary sclerosing cholangitis, autoimmune hepatitis or overlap syndrome
- Alcoholic liver disease
- Wilson's disease or hemochromatosis or iron overload
- Alpha-1-antitrypsin (A1AT) deficiency
- Prior known drug-induced liver injury within 5 years before Day 1
- Known or suspected hepatocellular carcinoma
-
History of liver transplant, current placement on a liver transplant list, or current Model for End-Stage Liver Disease (MELD) score >12. Subjects who are placed on a transplant list despite relatively early disease stage (eg, per regional guidelines) may be eligible as long as they do not meet any of the other exclusion criteria
-
Presence of hepatic decompensation, including:
- Gastroesophageal varices
- Ascites
- Hepatic encephalopathy
- Spontaneous bacterial peritonitis
- Hepatorenal or hepatopulmonary syndromes
-
Total bilirubin ≥2x upper limit of normal (ULN) at any Screening Visit (subjects with Gilbert's syndrome may be enrolled despite a total bilirubin level >2x ULN if their conjugated bilirubin is <2x ULN)
-
Creatine phosphokinase >5x ULN at Screening Visit 2
-
Serum creatinine ≥1.5 mg/dL at any Screening Visit
-
Serum alanine aminotransferase (ALT) >300 U/L at any Screening Visit
-
Platelet count <75,000/mm3 at any Screening Visit
-
Known positivity for human immunodeficiency virus (HIV) infection
-
Subjects with recent history (within 1 year of randomization) of cardiovascular disease or with history or planned cardiovascular interventions to treat atherosclerotic cardiovascular disease
-
Other concomitant disease, malignancy, or condition likely to significantly decrease life expectancy to <5 years, including known cancers (except carcinomas in situ or other stable, relatively benign conditions such as chronic lymphocytic leukemia) and moderate to severe congestive heart failure.
-
Known substance abuse, including inhaled or injected drugs in the year before Screening.
-
For female subjects: pregnancy, planned or potential for pregnancy and unwillingness to use effective birth control during the study, or breastfeeding
-
Participation in a clinical research study with any investigational product being evaluated for the treatment of diabetes or NASH in the 6 months before Day 1.
-
Receipt of any investigational product not being evaluated for the treatment of diabetes or NASH from Screening Visit 1 to Day 1, within 30 days prior to Day 1, or within 5 half-lives of the compound before Day 1 (whichever was longer)
-
Previous exposure to Obeticholic Acid
-
History of known or suspected clinically significant hypersensitivity to Obeticholic Acid or any of its components
-
Mental instability or incompetence, such that the validity of informed consent or ability to be compliant with the study is uncertain
-
Any other condition which, in the opinion of the Investigator, would impede compliance or hinder completion of the study
-
Acute cholecystitis or acute biliary obstruction
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- PARALLEL
- Arm && Interventions
Group Intervention Description 5 mg Obeticholic Acid Obeticholic Acid 5 mg Obeticholic Acid daily for the double-blind treatment period. 10 mg Atorvastatin titrating to 20mg. 10 mg Obeticholic Acid Obeticholic Acid 10 mg Obeticholic Acid daily for the double-blind treatment period. 10 mg Atorvastatin titrating to 20mg. Placebo Placebo One tablet daily for the double-blind treatment period. 10 mg Atorvastatin titrating to 20mg. 5 mg Obeticholic Acid Atorvastatin 5 mg Obeticholic Acid daily for the double-blind treatment period. 10 mg Atorvastatin titrating to 20mg. 10 mg Obeticholic Acid Atorvastatin 10 mg Obeticholic Acid daily for the double-blind treatment period. 10 mg Atorvastatin titrating to 20mg. 25 mg Obeticholic Acid Atorvastatin 25 mg Obeticholic Acid daily for the double-blind treatment period. 10 mg Atorvastatin titrating to 20mg. Placebo Atorvastatin One tablet daily for the double-blind treatment period. 10 mg Atorvastatin titrating to 20mg. 25 mg Obeticholic Acid Obeticholic Acid 25 mg Obeticholic Acid daily for the double-blind treatment period. 10 mg Atorvastatin titrating to 20mg.
- Primary Outcome Measures
Name Time Method The Effect of Obeticholic Acid on Low-density Lipoprotein (LDL) Concentration (Least Squares Mean Change From Baseline at Week 16) Baseline and Week 16 The effect of Obeticholic Acid on LDL metabolism in subjects with biopsy confirmed nonalcoholic steatohepatitis (NASH) and the ability of atorvastatin to modulate this effect as measured by change (least squares mean) from baseline at week 16 in LDL concentration
The Effect of Obeticholic Acid on LDL Particle Size (Least Squares Mean Change From Baseline at Week 16) Baseline and Week 16 The effect of Obeticholic Acid on LDL metabolism in subjects with biopsy confirmed NASH and the ability of atorvastatin to modulate this effect as measured by change from baseline (least squares mean) at week 16 in LDL particle size. It is LDL particle diameter size (nm) that is reported.
The Effect of Obeticholic Acid on LDL Particle Concentration (Total) (Least Squares Mean Change From Baseline at Week 16) Baseline and Week 16 The effect of Obeticholic Acid on LDL metabolism in subjects with biopsy confirmed nonalcoholic NASH and the ability of atorvastatin to modulate this effect as measured by change (least squares mean) from baseline at week 16 in LDL particle concentration (total)
- Secondary Outcome Measures
Name Time Method
Trial Locations
- Locations (22)
Consultants for Clinical Research
🇺🇸Cincinnati, Ohio, United States
University of Miamai, Schiff Center for Liver Diseases
🇺🇸Miami, Florida, United States
Mercy Medical Center, Institute for Digestive Health & Liver Disease
🇺🇸Baltimore, Maryland, United States
Duke University Medical Center
🇺🇸Durham, North Carolina, United States
American Research Corporation at the Texas Liver Institute
🇺🇸San Antonio, Texas, United States
ClinSearch
🇺🇸Chattanooga, Tennessee, United States
Texas Clinical Research Institute, LLC
🇺🇸Arlington, Texas, United States
Liver Associates of Texas, P.A.
🇺🇸Houston, Texas, United States
St. Joseph's Hospital and Medical Center
🇺🇸Phoenix, Arizona, United States
Scripps Clinic
🇺🇸La Jolla, California, United States
Inland Empire Liver Foundation
🇺🇸Rialto, California, United States
The Queen's Medical Center - Liver Center
🇺🇸Honolulu, Hawaii, United States
Florida Medical Clinic, P.A.
🇺🇸Zephyrhills, Florida, United States
Kansas City Research Institute
🇺🇸Kansas City, Missouri, United States
St. Louis University
🇺🇸Saint Louis, Missouri, United States
Cumberland Research Associates, LLC
🇺🇸Fayetteville, North Carolina, United States
University Gastroenterology Liver Center
🇺🇸Providence, Rhode Island, United States
Nature Coast Clinical Research
🇺🇸Inverness, Florida, United States
Medical University of South Carolina
🇺🇸Charleston, South Carolina, United States
South Florida Center of Gastroenterology
🇺🇸Wellington, Florida, United States
McGuire DVAMC
🇺🇸Richmond, Virginia, United States
Thomas Jefferson University
🇺🇸Philadelphia, Pennsylvania, United States